Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo

被引:27
作者
Kajiyama, H [1 ]
Shibata, V [1 ]
Terauchi, M [1 ]
Morita, T [1 ]
Ino, K [1 ]
Mizutani, S [1 ]
Kikkawa, F [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
D O I
10.1158/1078-0432.CCR-04-2395
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, numerous studies have shown that endothelin-1 (ET-1) is expressed in ovarian carcinoma and that ET-1 selectively acts as an autocrine or paracrine growth factor through the endothelin A receptor (ETAR), and is involved in cell proliferation, invasiveness, neovascularization, and prevention of apoptosis. Neutral endopeptidase 24.11 (NEP) is a cell surface aminopeptidase with a ubiquitous expression and is capable of degrading a number of bioactive peptides including ET-1. Our previous report showed that stromal NEP expression in ovarian carcinoma was down-regulated as the histologic grade advanced. Here, we confirmed that NEP was expressed in tumor cells as well as stromal tissues in ovarian carcinoma, and investigated the functions of NEP in this carcinoma. We showed that there was a significant decrease in cell proliferation and invasiveness with a reduction in the concentration of ET-1 in the conditioned medium on the overexpression of NEP in ovarian carcinoma cells. In addition, the overexpression of NEP enhanced susceptibility to paclitaxel, resulting in an increased occurrence of apoptotic morphologic change. Furthermore, tumorigenesis was reduced in vivo with the overexpression of NEP, down-regulation of both matrix metalloproteinase-2, and vascular endothelial growth factor expression. This evidence suggests that NEP functionally suppresses the progression of ovarian carcinoma and further study of this enzyme may reveal an effective way to target ET-1 for the treatment of this carcinoma.
引用
收藏
页码:1798 / 1808
页数:11
相关论文
共 26 条
[1]  
Bagnato A, 1999, CANCER RES, V59, P720
[2]  
Bagnato A, 1995, CLIN CANCER RES, V1, P1059
[3]  
Bagnato A, 1997, CANCER RES, V57, P1306
[4]   Breast cancer cell-associated endopeptidase EC 24.11 modulates proliferative response to bombesin [J].
Burns, DM ;
Walker, B ;
Gray, J ;
Nelson, J .
BRITISH JOURNAL OF CANCER, 1999, 79 (02) :214-220
[5]   Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms - Frequent expression in renal cell carcinoma and endometrial stromal sarcoma [J].
Chu, PG ;
Arber, DA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (03) :374-382
[6]  
Cohen AJ, 1996, CANCER RES, V56, P831
[7]  
Dai J, 2001, CLIN CANCER RES, V7, P1370
[8]   Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis:: Requirement for Akt activation [J].
Del Bufalo, D ;
Di Castro, V ;
Biroccio, A ;
Varmi, M ;
Salani, D ;
Rosanò, L ;
Trisciuoglio, D ;
Spinella, F ;
Bagnato, A .
MOLECULAR PHARMACOLOGY, 2002, 61 (03) :524-532
[9]   NEUTRAL ENDOPEPTIDASE 24.11 (ENKEPHALINASE) AND RELATED REGULATORS OF PEPTIDE-HORMONES [J].
ERDOS, EG ;
SKIDGEL, RA .
FASEB JOURNAL, 1989, 3 (02) :145-151
[10]   The expression and localization of neutral endopeptidase 24.11/CD10 in human gestational trophoblastic diseases [J].
Ino, K ;
Suzuki, T ;
Uehara, C ;
Nagasaka, T ;
Okamoto, T ;
Kikkawa, F ;
Mizutani, S .
LABORATORY INVESTIGATION, 2000, 80 (11) :1729-1738